研究关注：Biogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacy

## 事件概览

Here we go again? Biogen reported heavily anticipated Alzheimer’s data on Thursday morning, saying its tau-targeting drug BIIB080 did not me...

## 核心信息

Here we go again? Biogen reported heavily anticipated Alzheimer’s data on Thursday morning, saying its tau-targeting drug BIIB080 did not meet its primary endpoint in a Phase 2 study. But the company said it slowed ...

## 为什么值得关注

这条内容与 drug discovery 相关，可能影响科研选题、技术趋势判断或产业观察。BioDir 已根据来源、摘要长度、主题词和潜在影响给出 32 分的候选评分。

## 发布提示

发布前应核对原文链接、研究对象、样本规模、方法限制和结论边界。若来源为 bioRxiv 或 medRxiv，应明确标注其为预印本，尚未经过同行评议。